While the market headed south on Monday, a lot of stocks we follow did well. Here are five to watch.
Idera Pharmaceuticals had a good day on Monday after presenting positive clinical trial data for its cancer drug over the weekend. The stock popped 52 cents, or 13.6%, to $4.32, on 7 million shares, breaking out of its inverse head-and-shoulders bottoming pattern. The stock could extend very quickly to $5.25-.50 short-term, which is the high from earlier this year, followed by a secondary target of $7.00.
Universal Display has been in a steep up-channel for the last month, popping and flagging several times as it has risen from the $35 area to over $55. The company had reported strong third-quarter results early last month and was rumored to have its display technology included in future iPhones. The stock gained another 88 cents to $55.59 on 1.3 million shares on Monday. Key, short-term support is at around $51.75, with resistance, and our initial target, in the mid-$60's.
Rudolph Technologies broke out early last month and flagged, and then broke out again, and is currently pullng back in a bull wedge. It did gain 15 cents to $14.50 on 434,500 shares traded on Monday. If it does run through here, the maker of equipment to help chip manufacturers test for defects could see its shares reach the channel top near $18.00.
After breaking out of a wedge several weeks ago and pulling back to test support, NeoPhotonics appears to be popping again. The maker of components for communications networks gained 33 cents, or 3%, to $10.92 on Monday on 1.45 million shares. It reached $11.19 in June, and Monday's high was $11.15, so that's an area to watch. If it can get through there, it may explode, with the mid-channel target at around $14, and the top of the channel projecting to $19-$20.
After its IPO two months ago, NovoCure popped, pulled back and has coiled for the last six weeks. It looks like it broke out on Monday, up $2.34, or 9.4%, to $27.16, on 8 million shares, after the cancer-fighting biotech company was featured by Jim Cramer on Mad Money. It could very well get a new test of the high, with the target at $30-31 short term.
See more video chart analysis on these stocks.
This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.